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Abstract
The increased glycation of plasma apolipoproteins represents a possible major factor for lipid disturbances and accelerated
atherogenesis in diabetic patients. The glycation of apolipoprotein E (apoE), a key lipid-transport protein in plasma, was
studied both in vivo and in vitro. ApoE was shown to be glycated in plasma very low density lipoproteins of both normal
subjects and hyperglycemic, diabetic patients. However, diabetic patients with hyperglycemia showed a 2^3-fold increased
level of apoE glycation. ApoE from diabetic plasma showed decreased binding to heparin compared to normal plasma apoE.
The rate of Amadori product formation in apoE in vitro was similar to that for albumin and apolipoproteins A-I and A-II.
The glycation of apoE in vitro significantly decreased its ability to bind to heparin, a critical process in the sequestration and
uptake of apoE-containing lipoproteins by cells. Diethylenetriaminepentaacetic acid, a transition metal chelator, had no
effect on the loss of apoE heparin-binding activity, suggesting that glycation rather than glycoxidation is responsible for this
effect. In contrast, glycation had no effect on the interaction of apoE with amyloid L-peptide. ApoE glycation was
demonstrated to be isoform-specific. ApoE2 showed a higher glycation rate and the following order was observed:
apoE2s apoE4s apoE3. The major glycated site of apoE was found to be Lys-75. These findings suggest that apoE is
glycated in an isoform-specific manner and that the glycation, in turn, significantly decreases apoE heparin-binding activity.
We propose that apoE glycation impairs lipoprotein-cell interactions, which are mediated via heparan sulfate proteoglycans
and may result in the enhancement of lipid abnormalities in hyperglycemic, diabetic patients. ß 1999 Elsevier Science B.V.
All rights reserved.
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1. Introduction
Atherosclerosis represents a major complication in
diabetes and is a major cause of morbidity among
diabetic patients [1^3]. Several lipid abnormalities
accompanying diabetes, including increased levels
of VLDL and LDL and decreased levels of HDL
have been proposed as a major contributing factor
in atherogenesis in diabetic patients. These abnor-
malities are severer in patients under poor, glycemic
control and tend to decline at conditions of well-con-
trolled glucose homeostasis [4^7].
Glycation, a non-enzymatic reaction between the
free amino groups of protein and glucose, is believed
to be an important atherogenic factor in diabetic
patients [8], and it has been shown that the major
plasma lipoproteins, VLDL, LDL, and HDL, are
susceptible to glycation. Moreover, the glycation of
speci¢c apolipoproteins A-I, A-II, B, C-I and E has
also been described in hyperglycemic, diabetic pa-
tients [9^12]. Extensive glycation of apoB reduces
its a⁄nity to heparin and can totally block the rec-
ognition of LDL by the LDL receptor [13]. The
glycation of apoA-I alters the self-association and
lipid-binding properties of the protein [14] and also
leads to the abnormal association of apoA-I with
HDL and decreased lecithin-cholesterol acyltransfer-
ase (LCAT) activation by apoA-I in vivo [15,16].
Glycated HDL shows a decrease in its functional
ability to bind to the HDL receptor-binding site on
cells and to promote intracellular cholesterol e¥ux
[17,18]. In contrast, glycation of VLDL, which con-
tains several apolipoproteins as components, has
been less well studied. It has, however, been shown
that glycation decreases both the hydrolysis of
VLDL by lipoprotein lipase and its degradation in
skin ¢broblasts [19,20].
Although the glycation of plasma apoE has been
detected in hyperglycemic, diabetic patients, the
functional consequences of the process have not yet
been assessed. ApoE is a key lipid-transport apolipo-
protein in plasma and an important cholesterol-
transport protein in the brain [21,22], serving as a
ligand for several types of receptors, such as the
LDL receptor and the LDL receptor-related protein
(LRP). The binding of apoE to cellular heparan sul-
fate proteoglycans (HSPG) is a critical sequestration
event in LRP-mediated lipoprotein uptake [23]. The
high-a⁄nity binding of apoE to Alzheimer AL has
also been established [24^26]. Levels of apoE, as well
as apoE:apoB ratios are signi¢cantly increased in the
plasma triglyceride-rich lipoprotein fractions from
donors with non-insulin-dependent diabetes mellitus
[27].
The present paper describes a study of the glyca-
tion of apoE in vivo and in vitro. Glycation was
monitored as the formation of the Amadori product,
the earliest stable product of the Maillard reaction,
which represents the most important product for a
protein such as apoE with a short half-life [28].
In vivo, glycated apoE was found in the VLDL frac-
tion of both normal subjects and diabetic patients.
However, the extent of apoE glycation was 2^3-fold
higher in hyperglycemic, diabetic patients, as com-
pared to non-diabetic subjects. The rate of apoE
glycation in vitro was similar to that of albumin,
and the glycation of apoE signi¢cantly impaired its
binding to heparin as estimated by surface plasmon
resonance (SPR), a biosensor technology used for
biospeci¢c interaction studies [29,30]. Moreover, we
identi¢ed Lys-75 as the most likely site of apoE
glycation.
2. Materials and methods
2.1. Materials and lipoprotein isolation
Recombinant human apoE isoforms were puri¢ed
from Escherichia coli as described previously [31].
Synthetic AL [1^40] peptide was purchased from
Bachem (Switzerland). Sensor chips CM5 and SA
were obtained from Biacore AB (Sweden). Native
heparin was obtained from Sigma (USA), and poly-
clonal anti-apoE antibodies were purchased from
Calbiochem (UK). Plasma was obtained from fasting
donors and diabetic patients. VLDL (d6 1.006 g/ml)
were isolated from plasma by ultracentrifugation in
an RP 65-859 rotor (Hitachi, Japan) at 40 000 rpm
for 23 h at 18‡C. ApoE3 was puri¢ed from normal
and diabetic plasma VLDL as described elsewhere
[32].
2.2. Preparation of glycated proteins
Proteins at a ¢nal concentration of 50 Wg/ml were
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incubated in a 50 mM phosphate bu¡er, 0.15 M
NaCl, 5 mM sodium azide, pH 7.4, supplemented
with 100 mM D-glucose at 37‡C. Control samples
were incubated in the same bu¡er without glucose.
In some experiments 1 mM DETAPAC was added
to prevent oxidation. Afterwards the incubation sam-
ples were frozen until used in assays.
2.3. Immunoblotting and ELISA of glycated proteins
Samples of proteins or VLDL preparations were
reduced with sodium borohydride to convert Ama-
dori products to hexitol-lysine derivatives. One Wl of
freshly prepared 0.1 M sodium borohydride in 0.01
M NaOH was added to 20 Wl of the sample, which
was then incubated for 2 h at room temperature.
Reduced samples were subjected to 12% polyacryl-
amide gel electrophoresis in the presence of sodium
dodecyl sulfate, followed by transferring to nitrocel-
lulose membranes under semi-dry conditions using a
Semi-phor TE-70 (Hoefer). The membrane was
blocked with 3% BSA and reacted with a monoclon-
al anti-hexitol-lysine antibody [33] or polyclonal
anti-apoE antibodies (Calbiochem). The chemilumi-
nescence method was used for the detection of per-
oxidase activity with an ECL kit (Amersham, UK).
The membranes were exposed to the X-ray ¢lm (Fuji,
Japan) and the bands corresponding to the speci¢c
proteins were semiquanti¢ed by scanning the ¢lm.
Glycation index of apoE was estimated as the Ama-
dori product level determined by ¢lm scanning of the
apoE-containing band after normalization to the
apoE level of the band. Comparison of glycation
indexes of samples in the same membrane was per-
formed. ELISA was performed essentially as previ-
ously described [33].
2.4. Heparin biotinylation
Heparin was biotinylated using Biotin-LC-NHS
(Pierce, USA) [34]. Five mg of heparin from porcine
intestine mucosa (Sigma, USA) was dissolved in 2 ml
of 50 mM bicarbonate bu¡er, pH 8.5. Biotinylation
was performed in the presence of Biotin-LC-NHS,
pre-dissolved in dimethylformamide at a molar ratio
of heparin:biotin of 6:1 to exclude overlabeling. The
mixture was then incubated for 1 h at room temper-
ature, unreacted biotin was removed and the bu¡er
was changed to 25 mM Tris, pH 8.3, by centrifuga-
tion on a Centricon-3 (Amicon, USA).
2.5. Immobilization of ligands on sensor chips
SPR experiments were performed on a BIAcore
2000 apparatus (Pharmacia Biosensor, Sweden).
AL(1^40) was immobilized on a CM5 sensor chip
by amino coupling as described previously [25]. Bio-
tinylated heparin was immobilized on a streptavidin-
precoated SA sensor chip by injection of 35 Wl at a
concentration of 0.25 mg/ml at a £ow rate of 5 Wl/
min to reach saturation of the surface.
2.6. SPR experiments
Binding experiments were performed at 25‡C at a
£ow rate of 5 Wl/min. The running bu¡er was that
used for the glycation reaction. To study the binding
of proteins to heparin, 20 Wl of analyte in the running
bu¡er was injected over the heparin-containing sen-
sor chip for the association phase (contact time:
4 min). After 4 min of dissociation, the surface was
regenerated by injection of 10 Wl of 1.0 M NaCl in
phosphate bu¡er, pH 7.4. Interaction of proteins
with immobilized AL(1^40) was assessed by injection
of 20 Wl of analyte. Regeneration was performed by
the injection of 10 Wl of 4.0 M guanidine-HCl in
phosphate bu¡er. Dissociation and association rate
constants kdiss and kass were calculated by analysis of
sensorgrams using BIAevaluation software (Pharma-
cia Biosensor). The equilibrium dissociation constant
Kd was calculated as the ratio of mean kdiss/kass val-
ues.
2.7. Preparation of lysyl-endopeptidase-treated
peptides and mass spectrometry
Control and in vitro glycated apoE were S-carbox-
ymethylated and treated with 1% (w/w) lysyl-endo-
peptidase (Wako Pure Chemicals) for 24 h at 37‡C.
The peptides obtained were separated by RP-HPLC
on a Cosmosil C18 column (4.6U250 mm, Nacalai
Tesque). Chromatography was performed at a £ow
rate of 1 ml/min using a 15^75% gradient of acetoni-
trile. Detection was performed at 214 nm. The re-
solved peaks were collected, dried and dissolved in
50% acetonitrile. The molecular weight of the iso-
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lated peptides was estimated using matrix-assisted
laser desorption ionization time-of-£ight mass spec-
trometry (MALDI-TOF-MS) on a Voyager DL RP
mass spectrometer (PerSeptive Biosystems). Samples
for mass spectrometry were prepared in 50% aceto-
nitrile, 0.1% trichloroacetic acid using 0.5% K-cyano-
4-hydroxycinnamic acid as a matrix [35].
2.8. Amino acid sequencing
Protein sequencing of the separated glycated pep-
tide was performed on a gas-phase protein sequencer
G1000A and PTH-amino acids were quanti¢ed by
RP-HPLC on a liquid chromatograph (1090, Hew-
lett-Packard).
3. Results
3.1. ApoE glycation in vivo and its binding to heparin
ApoE glycation in human plasma was studied in
normal subjects and diabetic patients. Hexitol-lysine
contents in the apoE band and the apoE protein
contents were estimated by Western blotting using
the same membrane with the anti-hexitol-lysine anti-
body and the anti-apoE antibody, respectively. West-
ern blotting analysis of plasma VLDL demonstrated
that apoE was glycated in both control and diabetic
samples (Fig. 1A). The extent of glycation was calcu-
lated as a ratio of apoE Amadori product to apoE
protein. Glycation levels were increased 2^3-fold in
hyperglycemic patients, compared to non-diabetic
subjects (12.8 þ 2.3 vs. 5.2 þ 2.3, respectively) (Fig.
2, Table 1). Moreover, in vitro glycation of apoE
was comparable with the level of apoE glycation that
was observed in in vivo glycation (Fig. 1B). Re-
combinant apoE used in in vitro studies showed low-
er mobility on the gel because the protein had a His
tag consisting 34 amino acids useful for fast puri¢-
cation [31].
Binding of normal and diabetic apoE to heparin
was estimated using SPR to see whether there is any
e¡ect of glycation. Samples of apoE in 10 mM phos-
phate bu¡er, 0.15 M NaCl, pH 7.4, were injected
over a sensor chip containing immobilized heparin.
Binding of apoE from diabetic patients was signi¢-
Fig. 1. Comparison of glycation of apoE in vitro and in vivo.
(A) ApoE glycation in vitro in the presence of 100 mM glucose
after 0, 1 and 7 days (lanes 1^3, respectively; 0.5 Wg apoE),
plasma VLDL from normal subjects (lanes 4^6) and hyperglyce-
mic diabetic patients (lanes 7^9; 0.25 Wg apoE). Western blot-
ting analysis was performed using anti-hexitol-lysine antibodies.
Molecular masses of recombinant and plasma proteins are 40
and 34 kDa, respectively. (B) Estimation of the level of apoE
glycation in vitro as compared to in vivo. The mean of apoE
glycation in normal plasma VLDL was taken as 100%. Relative
glycation was calculated as the ratio (Amadori product)/(pro-
tein) by scanning densitometry of apoE bands on Western blot
membranes which were stained using antibodies for Amadori
product and for apoE, respectively.
Table 1
Comparison of normal individuals and diabetic patients
Control Diabetes
n 3 3
Age (years) 72 þ 15 65 þ 6
Glucose (mg%) 89 þ 16 158 þ 19
Cholesterol (mg%) 161 þ 44 158 þ 66
Triglycerides (mg%) 76 þ 12 94 þ 18
ApoE glycation index (arbitrary units) 5.2 þ 2.3 12.8 þ 2.3
ApoE glycation index was calculated after the analysis of plas-
ma VLDL. Mean and S.D. are shown.
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cantly decreased as compared to normal plasma
apoE (Fig. 3), suggesting involvement of the glyca-
tion reaction in the decreased a⁄nity. Since available
apoE proteins from patients were limited, we used
the recombinant apoE proteins for detailed analysis
in the following experiments.
3.2. In vitro glycation of apoE
For in vitro glycation, 50 Wg/ml of the protein in
the glycation bu¡er (50 mM phosphate bu¡er, 0.15
M NaCl, 5 mM NaN3, pH 7.4) was incubated with-
out glucose or in the presence of 25 or 100 mM D-
glucose. Western blotting analysis clearly showed
that the incubation of apoE at 37‡C for 1 week
had no e¡ect on its molecular weight (Fig. 4A), in-
dicating that fragmentation of apoE had not oc-
curred. In contrast, Amadori products were accumu-
lated in the apoE sample after incubation with 100
mM glucose as shown by Western blotting of the
reduced apoE using an anti-hexitol-lysine antibody
(Fig. 4B).
3.3. Quanti¢cation of formation of Amadori products
by ELISA
Glycation of apoE in 25 and 100 mM glucose
showed that the rate of Amadori product formation
was a nearly linear function of glucose concentration
and incubation time in the ranges employed (Fig.
5A). The glycation rate of apoE was detected to be
comparable to that for albumin (Fig. 5B). The results
indicate that apoE reacts with and is readily glycated
by glucose. A comparison of glycation of three com-
Fig. 3. SPR analysis of the binding of puri¢ed apoE from normal (1) and diabetic (2) plasma VLDL to immobilized heparin. Twenty
Wl of 1 WM (34 Wg/ml) apoE in 10 mM phosphate bu¡er, 0.15 M NaCl, pH 7.4, was injected at a £ow rate of 5 Wl/min for association
phase, followed by the dissociation phase.
Fig. 2. ApoE glycation in plasma VLDL of normal individuals
and hyperglycemic, diabetic patients. Relative glycation in the
groups was calculated as the ratio (Amadori product)/(protein)
by scanning densitometry of apoE bands on Western blot mem-
branes after reaction with antibodies for Amadori product and
apoE, respectively. Means and S.D. of three individuals in each
group are shown.
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mon apoE isoforms revealed that apoE2 had the
highest glycation rate (Fig. 5C). The order of apoE
isoforms, in terms of sensitivity for glycation, was as
follows: apoE2s apoE4s apoE3. Preliminary experi-
ments also demonstrated that apolipoproteins A-I
and A-II exhibited similar rates of Amadori product
formation to that of albumin (data not shown). To
examine the possible inhibition of apoE glycation by
heparin, the protein was incubated with 100 mM
glucose in the presence of 1% heparin. ELISA anal-
ysis showed that heparin had no detectable e¡ect on
total Amadori product accumulation in apoE. How-
ever, the inhibition of speci¢c glycation site(s) by
heparin cannot, at this time, be excluded.
3.4. E¡ects of apoE glycation on the binding
properties to heparin and AL
Functional characterization of glycated apoE was
performed using SPR. Heparin-binding and AL-
binding activities were analyzed. The degree of bind-
ing of apoE to heparin was reduced, compared with
control apoE incubated without glucose (Fig. 6A and
B, respectively). Spikes at the beginning and at the
end of injection re£ect a changing of running and
sample bu¡ers, i.e. bulk e¡ects. Incubation of apoE
in the presence of 100 mM glucose for 1 week re-
sulted in the signi¢cant loss of its heparin-binding
activity as compared with apoE incubated without
glucose. The a⁄nity of heparin-apoE interaction
was also decreased for glycated apoE. The apparent
Fig. 5. Characterization of glycation of apoE. (A) E¡ect of glu-
cose concentration on the glycation rate of recombinant apoE3
incubated in the absence (1) and in the presence of 25 mM (2)
or 100 mM (3) D-glucose. (B) Comparison of glycation rates of
BSA (1), human plasma apoE3 (2), and recombinant apoE3 (3)
incubated in the presence of 100 mM D-glucose. (C) Compari-
son of the glycation of apoE isoforms incubated in the presence
of 100 mM D-glucose. ELISA was carried out after reducing
the samples with sodium borohydride, using anti-hexitol-lysine
antibodies.
Fig. 4. In vitro glycation of apoE. Recombinant apoE3 at a
concentration of 50 Wg/ml was incubated in 50 mM phosphate
bu¡er, 0.15 M NaCl, 5 mM NaN3, pH 7.4 in the presence of
100 mM D-glucose at 37‡C. Western blot analysis was per-
formed using anti-apoE (A) and anti-hexitol-lysine antibodies
(B).
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Kd for the interaction was calculated to be 15 þ 6 nM
for apoE3 without incubation and 43 þ 2 nM for gly-
cated apoE (8 days of incubation) vs. 24 þ 2 nM for
matched control apoE. To distinguish possible e¡ects
of glycoxidation, 1 mM DETAPAC was added to
apoE samples before incubation. DETAPAC had
no e¡ect on the loss of its binding to heparin during
glycation. The data suggest that glycation of apoE
Fig. 6. SPR analysis of apoE binding to immobilized heparin. ApoE was incubated in the absence (A) or in the presence of 100 mM
glucose (B). Binding of glycated recombinant apoE3 to amyloid L-peptide (C). ApoE was incubated in 100 mM glucose. The incuba-
tion time (days) is indicated at the right of each sensorgram. Twenty Wl of the protein sample at a concentration of 50 Wg/ml was in-
jected at a £ow rate of 5 Wl/min for the association phase, followed by the dissociation phase.
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rather than glycoxidation is involved in the observed
diminished binding to heparin.
The analysis of apoE binding to AL demonstrated
that glycation had no e¡ect on this interaction (Fig.
6C), suggesting that glycation of apoE does not play
an important role in its binding to AL. The ¢nding
was consistent with our previous observation [25],
indicating that hydrophobic interactions are the driv-
ing forces for the binding.
3.5. Glucose binding sites on apoE
The recombinant apoE had His tag [31] in which
no additional lysine residue is present and thus could
not be glycated. Since the N-terminal K-amino group
of apoE is blocked in the recombinant protein, likely
candidates for glycation sites are the O-amino groups
of lysine residues. To assess the preferential site(s) of
apoE glycation, the glycated protein was cleaved
with lysyl-endopeptidase and the apoE peptides sep-
arated by RP-HPLC (Fig. 7A). ELISA analysis of
the separated apoE peptides indicated that the pep-
tides were glycated to di¡erent extents and that one
peak (fraction 16) was highly glycated (Fig. 7B). The
glycated peptides were further characterized by
MALDI-TOF-MS and by amino acid sequencing.
Fractions 15 and 16 were found to contain the
same two peptides. In total these two peaks represent
20% of the total Amadori products detected in
the apoE peptides. A comparison of amino acid se-
quences and molecular mass of these peptides to
those of apoE showed that the peptides correspond
to apoE peptides 76^95 and 73^95 (Table 2). The
fact that a glycated Lys-containing peptide cannot
be cleaved by lysyl-endopeptidase and Lys cannot
be detected at cycle by an automated amino acid
sequencer, indicates that Lys-75 represents the
glycated residue. MALDI-TOF-MS data showed an
increase of 165 Da in mass for the latter peptide,
consistent with formation of the glucose adducts.
Fig. 7. RP-HPLC of glycated apoE, after treatment with lysyl-endopeptidase, on a Cosmosil C18 column. The eluent was monitored
by absorbance at 214 nm (A). Fractions were collected and glycation of the peptides was analyzed by ELISA (B). The most exten-
sively glycated fractions were analyzed by mass spectrometry and by amino acid sequencing.
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Thus, we conclude that Lys-75 of apoE represents a
preferential site for glycation.
4. Discussion
Atherosclerosis represents a complication in most
diabetic patients [1,2]. Moreover, macrovascular dis-
ease is the major cause of death in about 80% of
diabetic patients [1,36]. Glycation of apolipoproteins
may be a factor in impaired lipid metabolism and
lipid abnormalities, such as increased levels of trigly-
ceride-rich lipoproteins and LDL, and decreased
HDL levels, which accompany diabetes [3,8].
ApoE glycation in plasma VLDL of control and
hyperglycemic diabetic subjects was analyzed. A
close correlation between the levels of glycemic con-
trol in diabetic patients and the glycation of lipopro-
teins has been observed [37]. The major portion of
glycated apoE has been observed in the triglyceride-
rich lipoproteins of hyperglycemic diabetics [10]. Us-
ing monoclonal anti-hexitol-lysine antibodies we
were able to detect the presence of glycated apoE
in control, non-diabetic subjects, which was not de-
tected in earlier studies [10]. ApoE glycation in
VLDL was 2^3-fold higher in hyperglycemic diabetic
patients, compared to control subjects. Analysis of
apoE heparin-binding activity demonstrated that
the protein from diabetic patients reveals signi¢-
cantly lower binding than the normal protein. The
results suggest a possible involvement of apoE glyca-
tion in the impaired degradation of VLDL in plasma
of poorly controlled diabetics.
In vitro apoE glycation was characterized using
anti-hexitol-lysine antibodies. These antibodies rec-
ognize the reduced Amadori product of the Maillard
reaction, which is then converted to advanced glyca-
tion end products (AGEs) and oxidation products.
Amadori product formation may be the most impor-
tant criterion of glycation for proteins with a short
Table 2
Comparison of peptides from the most highly glycated fraction with apoE fragments
Cycle Number of fraction
15 (component 1) 15 (component 2) 16
1 Ser (40.0) Ala (3.86) Ala (8.59)
2 Glu (158.3) Tyr (2.91) Tyr (7.53)
3 Leu (125.9) Lys (...) Lys (...)
4 Glu (136.6) Ser (0.94) Ser (1.64)
5 Glu (149.0) Glu (149.0) Glu (10.64)
6 Gln (109.0) Leu (3.32) Leu (5.73)

















Estimated mass 2283 2814 2813
Predicted mass 2285 2647 2647
Yields of each PTH-amino acid are shown in parentheses.
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half-life, such as apoE [28]. A comparison of the rate
of apoE glycation with that of proteins such as al-
bumin, apoA-I, and apoA-II suggests that the amino
groups of apoE are readily accessible for glycation.
Glycated apoE showed a diminished total binding
and a⁄nity to heparin, indicating that at least some
apoE molecules lost their ability to bind to heparin
or bound with lower a⁄nity. Thus, the lysine resi-
due(s) of the heparin-binding site(s) in apoE may be
involved in the Amadori rearrangement. After 1 week
of incubation in 100 mM glucose, the heparin-bind-
ing activity of apoE was signi¢cantly decreased. It
should be noted that the incubation of apoE without
glucose also results in some loss of heparin-binding
activity perhaps due to partial denaturation. Treat-
ment with DETAPAC demonstrated that inhibition
of apoE oxidation did not a¡ect the decrease in its
binding to heparin. We concluded that the glycation
of apoE, rather than glycoxidation, is responsible for
the loss of its binding to heparin. Moreover, earlier
we observed that the mild oxidation of apoE does
not a¡ect its binding to heparin (unpublished data).
Lysine residues in apoE are known to be involved
in the binding of apoE to heparin. Mutant forms of
ApoE with additional lysines show increased a⁄nity
to heparin and proteoglycans [38,39]. In contrast,
lack of lysine may result in loss of heparin-binding
activity [40]. Similar results were obtained in vitro
[41]. Thus, blocking of O-amino groups in lysine res-
idues due to glycation is likely involved in the loss of
the heparin binding activity of the protein. However,
possible conformational changes due to the amino
acid modi¢cation cannot be excluded either. The
heparin-binding activity of apoE is strongly linked
to its HSPG-binding activity. The latter is, in turn,
a critical interaction for the sequestration of apoE-
containing lipoproteins on the cell surface, a limiting
step in the uptake and degradation of triglyceride-
rich lipoproteins via the LDL receptor-related pro-
tein (LRP)-mediated pathway [42] as well as in
HSPG independent pathway [43,44]. The binding of
apoE to HSPG has also been proposed to be an
important factor in the e¡ects of apoE on cell pro-
liferation [45,46]. Moreover, the heparin-binding site
of apoE is part of a larger receptor-binding site,
which suggests that apoE glycation may signi¢cantly
a¡ect the interaction of apoE-containing lipoproteins
with apoE receptors. Further studies should elucidate
whether apoE glycation may change the recognition
of apoE-containing lipoproteins by HSPG and apoE
receptors.
The data herein show that apoE is glycated in an
isoform-speci¢c manner. ApoE2 was the isoform
most sensitive to glycation. It is well known that
individuals with apoE2 homozygosity may develop
type III hyperlipoproteinemia if they develop addi-
tional risk factors such as obesity or diabetes [21,23].
Moreover, the impairment of apoE heparin-binding
activity in apoE variants correlates with the severity
of type III hyperlipoproteinemia [40]. Thus, it might
be proposed that high susceptibility of apoE2 to
glycation explains, in part, the hyperlipoproteinemia
observed in diabetic patients with this isoform.
SPR analysis of apoE-AL interactions demon-
strated that glycation has no e¡ect on binding, indi-
cating that the lysine residues of apoE have little, if
any, involvement in this interaction. The data are in
accordance with evidence which suggests that apoE
binds to AL via hydrophobic forces [25,47]. In addi-
tion, several clinical studies failed to ¢nd a link be-
tween diabetes mellitus and Alzheimer’s disease
[48,49].
Preferential sites of glycation have previously been
determined for apoA-I and apoB. Lys-239 has been
proposed as the preferential site of apoA-I glycation
[50] and the 67 amino acid region which is located at
1791 residues in the NH2-terminal, putative LDL
receptor-binding domain has been shown to be the
major modi¢cation site in apoB, as evidenced by the
presence of advanced glycosylation end products
[51]. In the present work Lys-75 was found to be
the preferred site of apoE glycation. The modi¢ca-
tion of Lys-75 was estimated to be responsible for
20% of the total apoE glycation. The reason for the
high reactivity of the lysyl residue is obscure. The
local charge density of the region surrounding Lys-
75 in the apoE molecule may suppress its protona-
tion. The region is rich in glutamate residues (Glu-
70, Glu-77, Glu-79, Glu-80) [52], which may increase
the reactivity of the lysine O-amino group and stim-
ulate the Amadori rearrangement [53]. The high ac-
cessibility of Lys-75 to glucose due to its localization
in the molecule might also be a reason for its reac-
tivity. It is interesting to note that the distance be-
tween the N of the Lys-75 O-amino group and O of
the Glu-79 carboxy group is quite small and corre-
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lates with the glycation rate of apoE isoforms. Using
molecular simulation, the distance between Lys-75
and Glu-79 was calculated to be 2.78, 4.85 and
4.40 Aî in apoE2, apoE3 and apoE4, respectively.
Thus, apoE2, the most sensible form to glycation,
displays the closest localization to the putative cata-
lyst. The role of this lysyl residue in the binding of
apoE to heparin is not clear. Fragments apoE(129^
169) and apoE(202^243) have been shown to be the
sequences which are critical for heparin binding
[41,54,55]. However, participation of lysyl residues
other than those localized in these fragments cannot
be ignored in apoE-heparin binding. The heparin-
binding fragments of apoE contain several lysyl res-
idues that may be modi¢ed by Amadori rearrange-
ment.
In conclusion, the glycation of apoE signi¢cantly
decreases its heparin-binding activity suggesting an
impairment of HSPG binding as well. ApoE was
glycated in an isoform-speci¢c manner. Nevertheless,
the precise mechanism for this remains to be eluci-
dated. Lys-75 was identi¢ed as a preferred site of
apoE glycation. Amadori products were detected in
VLDL apoE of both non-diabetic and hyperglycemic
diabetic subjects and diabetic apoE revealed lower
binding to heparin. A higher apoE glycation level
in hyperglycemic conditions indicates the possible in-
volvement of apoE glycation in lipid abnormalities in
diabetic patients under poor glycemic control.
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